| Document |
Document Title |
|
WO/2017/170970A1 |
A composition for controlling microsporidia in fishes is prepared by using, as an active ingredient, at least one kind of compound selected from the group consisting of a compound represented by general formula (I) [wherein R2, R4, R5, R...
|
|
WO/2017/163171A1 |
The present invention relates to a vaccine composition based on a recombinant polypeptide chimera composed of specific epitopes of human and mice CD4+ and CD8+ T lymphocytes derived from four Leishmania proteins (LiHypl, LiHyp6, LiHyV an...
|
|
WO/2017/164108A1 |
The compound according to the present invention, represented by formula (1) [where A1 represents a nitrogen atom or CR4, R4 representing a hydrogen atom or the like, any one of A2, A3, and A4 represents a nitrogen atom and the remainder ...
|
|
WO/2017/163181A1 |
The present invention relates to a vaccine composition composed of two immnogenic proteins defined by SEQ ID No. 1 and 2, and to the use thereof for treating and/or preventing canine and human cutaneous and visceral leishmaniasis.
|
|
WO/2017/159618A1 |
The purpose of the present invention is to provide a compound having a high activity against pests. The present invention provides: a substituted pyridine compound represented by formula (I) [wherein R1 represents an alkyl group or the l...
|
|
WO/2017/159759A1 |
[Problem] The present invention addresses the problem of providing an additive and feed for controlling fish parasitic diseases in the culture of fish, said additive and feed being characterized by characterized by containing β-1,4-mann...
|
|
WO/2017/161387A1 |
Synthetic drug development is slow and costly, often running into the billions of dollars. While the benefits of various abundant and inexpensive natural products, including natural oils and extracts, have been postulated and speculated ...
|
|
WO/2017/157899A1 |
The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligo...
|
|
WO/2017/155103A1 |
Provided is a novel pest control agent, particularly a pesticide or a miticide. A condensed heterocyclic compound represented by formula (1), a salt of the compound, or an N-oxide of the compound or the salt. [Q represents a structure re...
|
|
WO/2017/155465A1 |
The present invention provides a compound belonging to furanocoumarin derivative having core structure (A) as given below, its pharmaceutically acceptable salt, isomer or a combination thereof for the treatment and/or prevention of a par...
|
|
WO/2017/150174A1 |
Provided is a pharmaceutical composition for the treatment or prevention of Plasmodium diseases, the pharmaceutical composition being characterized by containing at least one quinazoline derivative represented by general formula (I) or a...
|
|
WO/2017/146226A1 |
The present invention addresses the problem of developing and providing a novel agricultural/horticultural insecticide in view of the fact that, in crop production, such as agriculture and horticulture, damage by harmful insects, etc., i...
|
|
WO/2017/146221A1 |
The present invention addresses the problem of developing and providing a novel agricultural/horticultural insecticide in light of factors in agricultural and horticultural crop production such as the damage caused by harmful insects, wh...
|
|
WO/2017/144517A1 |
A series of 3-imino-5-methyl-1,2,4-thiadiazinane 1,1-dioxide derivatives of formula (I), substituted in the 5-position by a phenyl moiety which in turn is meta-substituted by an optionally substituted fused bicyclic heteroaromatic ring s...
|
|
WO/2017/143964A1 |
The present invention provides a novel high-efficiency antimalarial drug, and specifically, the present invention provides applications of Quisinostat, analogs thereof, or pharmaceutically acceptable salts thereof in treating malaria. Th...
|
|
WO/2017/146220A1 |
The present invention addresses the problem of developing and providing a novel agricultural and horticultural insecticide because of factors such as existing devastation to crop production in agriculture, horticulture, etc., caused by i...
|
|
WO/2017/142843A1 |
The present invention provides polypeptides useful as antigens expressed at the pre-erythrocytic stage of the malaria parasite. The antigens can be utilized to induce an immune response and sterile protection against malaria in a mammal ...
|
|
WO/2017/137448A1 |
Several parasites responsible for mammalian diseases are dependent on cysteine proteases for various life-cycle functions. Inhibition or decreasing function of specific cysteine proteases can be useful in the treatment and/or prevention ...
|
|
WO/2017/136556A1 |
The invention relates to inhibitors of dihydrotolate reductase and pharmaceutical preparations thereof. The invention further relates to methods of treatment of parasitic infections, such as T. gondii, T. cruzi, P. falciparum, T. hrucei,...
|
|
WO/2017/123946A1 |
Compositions and methods for treating or reducing the severity or likelihood of occurrence of a parasitic worm or helminth infection in a subject are described. The methods include administering to the subject a therapeutically effective...
|
|
WO/2017/124087A1 |
The present disclosure provides compounds of Formula (I'), Formula (II), and Formula (III). The compounds described herein may useful in treating and/or preventing protozoan infections in a subject in need thereof, treating and/or preven...
|
|
WO/2017/121464A1 |
The present disclosure relates to compositions for the treatment of chitin-containing microorganism infection or colonization of an animal. The methods, systems and kits provided herein facilitate termination and/or inhibition of prolife...
|
|
WO/2017/120419A1 |
The present disclosure relates to the use of hepcidin in therapeutic methods for the treatment of various conditions in which decreasing serum iron concentration may be beneficial.
|
|
WO/2017/119928A1 |
The invention relates to extended-release formulations comprising: (i) a poorly water-soluble active pharmaceutical ingredient; and (ii) a non-aqueous liquid vehicle comprising (a) a hydrophobic lipid comprising a glyceryl ester of a C6 ...
|
|
WO/2017/120575A1 |
The disclosure provides compounds of the formula I and the pharmaceutically acceptable salts thereof. The variables, e.g. R1, R2, R3, R4, A, B, J, V, W, M, J and Ar are defined herein. The disclosure also provides pharmaceutical composit...
|
|
WO/2017/112678A1 |
Disclosed herein; are novel compounds for treating apicomplexan parasite related disorders, methods for their use; cell line and non-human animal models of the dormant parasite phenotype and methods for their use in identifying new drugs...
|
|
WO/2017/108954A1 |
The present invention relates to formulations for controlling parasites, comprising a combination of a macrocyclic lactone compound and levamisole wherein the levamisole is in particulate form suspended in triacetin and has an average ef...
|
|
WO/2017/106951A1 |
The present invention describes novel azo-stilbenoids as leishmanicidal agents. The present invention relates to the fields of organic synthesis and clinical pharmacology.
|
|
WO/2017/103020A1 |
The present invention generally relates to an immunogenic construct,useful for redirecting an EBV-existing immune response towards an undesired target cell and/or microorganism,to methods for preparing said conjugate, to a pharmaceutical...
|
|
WO/2017/100849A1 |
The invention relates to compounds which are useful as inhibitors of 6-oxopurine phosphoribosyltransferases such as hypoxanthine-guanine-(xanthine) phosphoribosyltransferase (HG(X)PRT).
|
|
WO/2017/104741A1 |
Provided is a compound represented by formula (I) or a salt or N-oxide compound thereof. [In formula (I), A1 to A4 groups each independently denote a carbon atom or nitrogen atom, X1 denotes a C1-6 alkyl group or the like, n denotes the ...
|
|
WO/2017/097245A1 |
The present invention relates to the field of pharmaceutical compounds and preparation methods thereof, and particularly relates to a Cephalotaxus ester alkaloid, and preparation method and use thereof. The Cephalotaxus ester alkaloid ha...
|
|
WO/2017/097855A1 |
The present invention relates to an injectable composition comprising ricobendazole, lecithin and at least one pharmaceutically acceptable excipient.
|
|
WO/2017/098514A1 |
Disclosed a method of treating a disease or a disorder characterized by protease activity. A pharmaceutical composition for treating a disease or a disorder characterized by protease activity is further disclosed. A method of detecting a...
|
|
WO/2017/099034A1 |
Provided is a novel treatment strategy for anti-PD-1 antibody treatment. A pharmaceutical composition including at least one substance selected from the group consisting of (i)-(iii) below, administered before, after, or simultaneously w...
|
|
WO/2017/098274A1 |
The invention provides the use of zidovudine in combination with colistin for treating a microbial infection, wherein the concentration ratio of zidovudine to colistin is from about 8:1 to about 1:2.
|
|
WO/2017/096530A1 |
A hot-melt extruded solid dispersion composition, a method for preparing same and a use of the composition in preparation of medicines for preventing and/or treating diseases caused by Plasmodium. The composition comprises, according to ...
|
|
WO/2017/094750A1 |
There has been a demand for the development of novel agricultural and horticultural insecticides because pests and the like still cause heavy damage to crops produced in agriculture, horticulture, and the like, and pests resistant to exi...
|
|
WO/2017/094790A1 |
The present invention provides a 1,2,3-triazole derivative represented by general formula (1) and an insecticide/acaricide having a 1,2,3-triazole derivative as an active ingredient. In general formula (1), R represents a C1-C6 alkyl gro...
|
|
WO/2017/094204A1 |
An object is to provide a novel anti-Acanthamoeba agent. Provided is an anti-Acanthamoeba agent comprising luliconazole as an active ingredient.
|
|
WO/2017/089389A1 |
The invention relates to a compound of formula (I) wherein R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used in the treatment of Human African TRypanosomiasis.
|
|
WO/2017/089453A1 |
A series of 2-imino-6-methyltetrahydropyrimidin-4(lH)-one derivatives, substituted in the 6-position by a phenyl moiety which in turn is meta-substituted by an optionally substituted unsaturated fused bicyclic ring system containing at l...
|
|
WO/2017/089163A1 |
The present invention relates to detergents and cleaning agents, containing at least one protease and at least one organic compound of formula (I), said compound acting as a protease inhibitor and thus being a suitable enzyme stabilizer,...
|
|
WO/2016/187586A9 |
Described herein are composition and methods related to targeting the Nf1-Ras-Ets axis, that when perturbed, is identified as playing a role in initiation and maintenance in glioma. A postnatal, mosaic, autochthonous, glioma model that c...
|
|
WO/2017/079909A1 |
An anthelmintic traditional Chinese medicine, comprising: 30 g of fructus mume, 15 g of areca catechu, 7.5 g of Glycyrrhiza uralensis, 12 g of Angelica sinensis, and 15 g of Wolfiporia extensa.
|
|
WO/2017/083681A1 |
The presently-disclosed subject matter relates to crosslinkers, compositions, and methods for trapping a target of interest on a substrate of interest. The methods may be used to inhibit and treat pathogen infection and provide contracep...
|
|
WO/2017/077911A1 |
A compound represented by formula (I) or an N-oxide compound thereof has an excellent controlling effect on arthropod pests. (In the formula, A1 represents a nitrogen atom or CR4; R4 represents a hydrogen atom or the like; R1 represents ...
|
|
WO/2017/077968A1 |
A condensed heterocyclic compound represented by formula (II), in which Q represents a group represented by formula Q-1 or a group represented by formula Q-2, has an excellent control effect on arthropod pests (wherein, Z represents a ni...
|
|
WO/2017/072523A1 |
The present invention provides compounds such as delamanid for use in the treatment of a parasitic disease caused by or associated with parasites selected from -the Order Kinetoplastida consisting of species belonging to the genera Leish...
|
|
WO/2017/075189A1 |
Fusion proteins comprising human FH domains 18-20 (FH18-20) linked via an optional linker to IgG Fc, wherein the FH has mutation of D to G at position 1119 in domain 19; FHD1119G/Fc), and methods of use thereof, e.g., to treat pathogen i...
|
